Zacks Research Has Positive Outlook of BIO FY2024 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research raised their FY2024 earnings per share estimates for Bio-Rad Laboratories in a note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $10.18 for the year, up from their prior estimate of $9.46. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.28 EPS, FY2025 earnings at $11.44 EPS, Q1 2026 earnings at $3.15 EPS and Q2 2026 earnings at $3.08 EPS.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the company earned $2.33 earnings per share.

BIO has been the subject of a number of other reports. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target for the company. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Citigroup raised their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada lifted their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Up 0.6 %

BIO stock opened at $338.24 on Monday. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The business has a 50 day moving average price of $340.63 and a two-hundred day moving average price of $316.68. The company has a market cap of $9.47 billion, a price-to-earnings ratio of -12.36 and a beta of 0.93. Bio-Rad Laboratories has a twelve month low of $262.12 and a twelve month high of $387.99.

Institutional Trading of Bio-Rad Laboratories

Several hedge funds have recently added to or reduced their stakes in the company. Avior Wealth Management LLC lifted its holdings in Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after purchasing an additional 32 shares during the last quarter. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Wahed Invest LLC raised its holdings in Bio-Rad Laboratories by 14.0% in the 1st quarter. Wahed Invest LLC now owns 399 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 49 shares in the last quarter. Capital Advisors Ltd. LLC raised its holdings in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 62 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Bio-Rad Laboratories by 9.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company’s stock valued at $259,000 after acquiring an additional 82 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bio-Rad Laboratories

In related news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at approximately $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.50% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.